Area of research
Public Health, Environmental and Occupational Health · Oncology
Research interest
Research interests include Acute Lymphoblastic Leukemia research, CAR-T cell therapy research, Childhood Cancer Survivors' Quality of Life, and Lymphoma Diagnosis and Treatment.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study.
A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Safety profile of asparaginase<i>Erwinia chrysanthemi</i>in a large compassionate‐use trial
Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL).
L-Asparaginase (L-ASP) Related Toxicities with Asparaginase Erwinia Chrysanthemi in a Large Compassionate Use Protocol.